Splicing Factor 3b Subunit B1 (SF3B1) Gene Mutation Analysis
The SF3B1 gene at 2q33.1 codes for the protein, splicing factor 3b subunit B1 (SF3B1). The protein serves as a structural component (subunit B1) of splicing factor 3b. Splicing factor 3b in combination with splicing factor 3a and 12s RNA unit forms the U2 small nuclear RNA (U2 snRNA). The U2snRNA is an important complex required for a post-translational modification of mRNA involving the removal of introns from the pre-mRNA. SF3B1 is therefore an integral component of the spliceosome and is essential for mRNA splicing and formation of functional proteins. Mutations in the SF3B1 gene may result in altered SF3B1 protein function leading to defective mRNA splicing and synthesis of dysfunctional/ non-functional proteins.
Mutations in the spliceosome have been associated with a variety of diseases. Somatic mutations in the SF3B1 gene have specifically been associated with myelodysplastic syndromes (MDS). Approximately 30-35% of MDS patients have mutations in this gene which is clinically linked to the presence of ringed sideroblasts (RS) in the dysplastic bone marrow. Approximately 80% of the patients with MDS-RS carry the mutated gene. MDS patients with SF3B1 mutations also tend to have higher platelet counts and lower percentage of bone marrow blasts compared to MDS patients with wild-type SF3B1. Research has shown that SF3B1 mutation is a favorable prognostic factor for overall survival (OS) and risk of disease progression in MDS patients. SF3B1 mutation is commonly diagnosed using next-generation sequencing (NGS) or PCR. SF3B1mutations are also associated with myeloid (2-5%) and lymphoid leukemia (5-6%).
- Useful in diagnosing myelodysplastic syndrome
- Aids in the screening of individuals with a familial history of myelodysplastic syndrome
- Helpful in predicting the prognosis of myelodysplastic syndromes patients
A positive result indicates the presence of mutations in the SF3B1 gene, suggestive of MDS or MDS-RS.
A negative result indicates the absence of mutations in the SF3B1 gene, however, doesn’t rule out the possibility of MDS or MDS-RS.
Negative for mutations analysis (no mutations or pathogenic variants detected)
Whole blood, EDTA (Lavender-top).
Stability
- Ambient: 1 day
- Refrigerated: 3 days
- Frozen: 1 week
- Blood. 2021 May 27;137(21):3003. [PMID: 32347921]
- Biomark Res. 2020 Sep 3;8:38. [PMID: 32905346]
- Front Oncol. 2022 Jun 27;12:905490. [PMID: 35832562]
- Cancers (Basel). 2022 Oct 8;14(19):4927. [PMID: 36230848]